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With about 1.5 million new cases per year, 
lung carcinoma is the most frequent can-
cer in the world; it is also the first killer in 
adult patients, accounting for more than 
a fifth of deaths from cancer (Ferley et al., 
2008). It is partly preventable with smok-
ing cessation and it is slowly decreasing 
in the developed countries because of the 
many campaigns against tobacco addiction 
developed in the last decades but this is not 
the case in developing countries. In addi-
tion, we are observing a growing amount 
of lung cancer in females and in the never 
smoker population which may represent a 
significant amount of lung tumors in some 
series (Ferley et al., 2008). Since multiple 
pathways implicated in the development 
of lung tumors can now be better identi-
fied, several new therapeutic options may 
now be offered to patients. Nevertheless, the 
heterogeneity of non-small cell lung cancer 
(NSCLC) make it a particularly complex 
and unpredictable disease at presentation. 
A large number of new molecular targets are 
reported every year that may potentially be 
of interest for drug development. However, 
only very few targeted agents have reached 
the registration step up to now. There are 
several reasons for these frequent failures. 
They include (i) not predominant altera-
tions of pathways, (ii) multiplicity of poten-
tially predominant alterations, (iii) lack of 
specificity of targeted molecules, (iv) sub-
optimal strategies of registration, often 
related to an excessive speed in the design 
and launch of clinical trials mostly focused 
on registration requirements.
Thousands of teams are working on 
these issues worldwide but the processes 
of publication are not flexible. They are 
generally slow when any signal, positive or 
negative, should be published as soon as it 
is discovered.
That is the reason why on-line journals 
with the fastest review process must be 
developed in order to ensure a large divul-
gation of the most recent biological and 
clinical data.
Frontiers in Thoracic Oncology wants to 
offer this opportunity to the many funda-
mental and translational researchers who 
work on thoracic tumors and particu-
larly NSCLC, the most frequent thoracic 
malignancy.
The major fields to be considered for 
NSCLC in the next decade include preven-
tion, diagnostic procedures, surgery, radio-
therapy, chemotherapy, targeted agents and 
vaccines, and the strategic management of 
each lung cancer patient at different stages 
of the disease.
Prevention is a key issue for the control 
of cancer. Smoking cessation in the world 
would prevent the majority of lung tumors. 
Nevertheless, up to 30% of lung cancer are 
diagnosed in never smokers in the devel-
oped countries and a lot remains to be 
explored to identify other potential agents 
responsible for the development of adeno-
carcinoma in particular.
Chemoprevention in patients at high risk 
of development of lung cancer is another 
research area that has so far not been fully 
exploited, especially in view of the explo-
sion of knowledge about the molecular 
abnormalities that have been identified in 
this disease. Large randomized studies per-
formed in the 1980s and 1990s have been 
substantially negative, but they were mainly 
based on weak epidemiological assump-
tions rather than biological evidence.
Diagnostics have considerably evolved 
in the last 20 years and positron emission 
tomography (PET) scan, endobronchial 
ultrasound (EBUS), and transesophageal 
ultrasound (EUS) are now part of an accu-
rate preoperative assessment of potentially 
operable patients in most referral centers. 
But diagnostics also include the molecular 
profile of each tumor. An explosion of new 
targets have been observed in the last decade, 
several of which having already led to the 
development of new targeted agents (EGFR, 
ELM4–ALK in particular). More than half 
patients with lung adenocarcinoma have a 
single driver mutation according to the Lung 
Cancer Mutation Consortium (The National 
Lung Screening Trial Research Team, 2011). 
An extensive molecular profile of each 
tumor is becoming a standard in the most 
experienced centers. Proteomics are still in 
their early development era but they might 
play a major role in the very near future.
On an other hand, the role of low-dose 
CT scan for early detection of lung cancer 
will probably increase in the next future 
since the National Cancer Screening Trial 
recently reported a benefit of three yearly 
CT scans compared to chest-X-rays in a 
selected population at risk (Kris et al., 2011). 
Abnormalities in the tissues surrounding 
the tumor may potentially allow identifying 
those micro-nodules (<1 cm) most likely to 
be malignant.
Surgery
Technological advances, personal experi-
ence, and knowledge generated from clinical 
trials continue to improve our understand-
ing on the possibilities offered by surgery 
for staging and surgical management of 
patients with lung carcinoma.
There have been significant advances 
in evaluating the role of surgery as part 
of multimodality management in patients 
with potentially resectable primary tumors 
and mediastinal lymph node involvement. 
Data from the recently published IASLC 
staging classification suggest that patients 
with single level N2 disease have the same 
survival as patients with multi-level N1 dis-
ease, and this has led to the questioning of 
the rationale of excluding all patients with 
N2 disease from surgery (Rusch et al., 2007). 
Moreover clinical trials of induction chem-
otherapy in patients with N2 disease sug-
gest similar outcomes in survival between 
operable patients randomized to surgery or 
further radiotherapy (Shepherd et al., 1998; 
Johnstone et al., 2002; van Meerbeeck et al., 
2007; Albain et al., 2009).
Lung sparing will probably be one of the 
priorities of lung cancer management in the 
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been observed except for the angiogenesis 
inhibitor bevacizumab, a monoclonal anti-
body targeting vascular endothelial growth 
factor (Sandler et al., 2006). Cetuximab, a 
monoclonal antibody directed against the 
epidermal growth factor receptor, has also 
been evaluated extensively with chemother-
apy for NSCLC. Although all trials demon-
strated higher response rates, most failed 
to confirm either a statistically significant 
or clinically meaningful survival benefit 
(Pirker et al., 2009).
Numerous predictive and prognostic 
markers have been evaluated in NSCLC, 
but until recently, no single molecular 
marker has been found useful for either 
patient selection or to select specific drugs 
(Shepherd and Rosell, 2007; Coate et al., 
2009).
In the last years, several randomized 
trials have compared the EGFR Tyrosine 
kinase inhibitors gefitinib and erlotinib to 
standard chemotherapy. All these studies 
have showed that patients with sensitizing 
mutations in exons 19 or 21 of the EGFR 
TK domain, derived significantly greater 
benefit from EGFR TKI Inhibitors, whereas 
the opposite was true for patients with wild-
type EGFR (p < 0.0001; Mok et al., 2009; 
Maemondo et al., 2010; Mitsudomi et al., 
2010; Rosell et al., 2011). Gefitinib has been 
the first agent to be approved based on a 
molecular test in NSCLC.
It has always been admitted that six 
cycles of first-line chemotherapy were 
enough, mainly because the toxicity of con-
tinued doublet therapy. Recently, however, 
there has been renewed interest in evaluat-
ing maintenance therapy with single-agent 
chemotherapeutic agents or molecularly 
targeted agents. The largest and most con-
vincing trial assessed the value of mainte-
nance pemetrexed in patients with NSCLC 
not progressing after four cycles of doublet 
chemotherapy. This study demonstrated 
both a statistically significant and a highly 
meaningful survival benefit for patients 
with non-squamous histology who received 
maintenance pemetrexed (Ciuleanu et al., 
2009). An advantage for maintenance has 
also been reported with erlotinib (Cappuzzo 
et al., 2010).
Currently docetaxel, pemetrexed (in 
non-squamous carcinoma only) and the 
EGFR TKIs (erlotinib and gefitinib) are 
approved for the second-line treatment of 
NSCLC. These agents all have been shown 
A comparison of preoperative versus post-
operative chemotherapy has been done in 
the NATCH trial. No significant difference 
was observed among patients in this trial 
(Felip et al., 2009). Targeted agents and vac-
cine therapy are also being evaluated as an 
adjuvant treatment for operable NSCLC. 
Randomized studies are ongoing (Tyagi 
and Mirakhur, 2009).
Rather than asking whether neo-adju-
vant or adjuvant chemotherapy should be 
preferred, the key issue may be to deter-
mine which patients should be treated with 
peri-operative medications. Some tumor 
markers such as ERCC1, RRM1, MSH, beta-
tubulin, or BRCA1 may have a predictive 
value for selecting those patients who will 
mostly benefit from adjuvant treatments 
(Olaussen et al., 2006; Rosell et al., 2007; 
Seve et al., 2007; Zheng et al., 2007; Kamal 
et al., 2010). Developing molecular-based 
therapeutic strategies will certainly be one 
of the major challenges over the next few 
years. The neo-adjuvant approach offers 
a unique opportunity to test new drugs 
and to compare the tumor characteristics 
prior to and following induction therapy 
(Altorki et al., 2010). Several randomized 
adjuvant studies have recently been initi-
ated in Europe and in North America, based 
on the molecular characteristics of patients 
tumor.
The benefit obtained with the combi-
nation of radiotherapy and chemotherapy 
in locally advanced inoperable NSCLC is 
modest but significant and well established. 
Several randomized trials comparing radio-
therapy–chemotherapy given sequentially 
or concomitantly have suggested a better 
outcome when both modalities are given 
early and simultaneously (Auperin et al., 
2006). But there is still room for a large 
improvement with the use of cytotoxic and 
targeted agents in combination with mod-
ern radiotherapy.
Platinum-based chemotherapy still 
remains the standard treatment for most 
of fit patients with advanced NSCLC; Drug 
selection has not been based on histologi-
cal subtype until recently when it was rec-
ognized that the multi-targeted anti-folate 
agent, pemetrexed was less active in patients 
with squamous carcinoma (Scagliotti et al., 
2009). The addition of targeted agents to 
platinum-based doublets has been studied 
extensively in numerous clinical trials over 
the past decade and no additional benefit has 
from partial preservation in the manage-
ment of cancer. The option for patients with 
limited lung function have included bron-
choplastic and angioplastic sleeve resections 
and, when this is suitable, sublobar resec-
tion (in particular segmentectomy), where 
as much as possible of the normal lung is 
preserved. Limits of economic dissection 
and preventive treatment of preserved 
lung tissues are still investigational at the 
moment.
Extensive surgery for some T4 tumors 
is another area of potential improvement 
and debate since a complete resection may 
be the most appropriate curative treatment 
for such patients.
radiotherapy
Radiotherapy has an important role in 
both the curative and palliative treatment 
of NSCLC. Approximately three-fourth of 
patients with NSCLC eventually benefit 
from radiotherapy (Delaney et al., 2003). 
Recent advances in radiotherapy for lung 
cancer have been more strongly influenced 
by developments in technology rather than 
by an improved understanding of the radio-
biology of the disease.
Precise definition of the tumor anatomi-
cal extent is critical for accurate placement 
and shaping of the radiotherapy beams 
together with gating techniques. With 
recent advances in stereotactic radiother-
apy (Baumann et al., 2009) and with the 
introduction of radiofrequency ablation 
(Simon et al., 2007), elderly patients, those 
with poor lung function and those with 
local relapse and those patients who are not 
candidate for a surgical resection can now 
be offered a wide range of local therapeutic 
modalities.
Chemotherapy, targeted agentS, 
and vaCCineS
Despite optimal surgical management, 
5-year survival rate of resected NSCLC 
ranges between 30 and 80% according to 
pathological stage. The update of the indi-
vidual data-based NSCLCCG meta-analysis 
has showed a significant benefit for adju-
vant cisplatin-containing chemotherapy 
with a 4% improvement of survival at 
5 years (HR = 0.86; Stewart et al., 2007). 
A similar benefit has been reported with 
preoperative chemotherapy in another 
recent meta-analysis (5% improvement at 
5 years; HR = 0.88; Burdett et al., 2011). www.frontiersin.org  September 2011  | Volume 1  |  Article 29  |  3
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in drug registration processes and the aca-
demic part of the job, i.e., the optimal use 
of our armamentarium for each patient at 
the right time, is still pending. The next gen-
eration of clinical trials will have to include 
all these questions through large academic 
collaborations.
other thoraCiC malignanCieS
Several other thoracic malignancies are 
also candidate for a new molecular-based 
therapeutic management. Because they are 
less frequent, many of them have not ben-
efited from recent research and/or are not 
in the scope of pharmaceutical companies. 
There is no doubt that small cell lung can-
cer tumors, mesothelioma, and mediastinal 
tumors are also to be considered.
in ConCluSion
Thousands of teams are working on these 
issues worldwide but the processes of pub-
lication are not flexible. They are slow when 
any signal, positive or negative, should be 
published as soon as it is discovered. That 
is the reason why an on-line journal with 
the fastest review process would be highly 
appreciated and would be extremely 
time-saving.
Frontiers in Thoracic Oncology wants to 
offer this opportunity to the many funda-
mental and translational researchers who 
work in the field of thoracic malignancies.
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